Sense of Congress

It is the sense of Congress that— (1) the biggest roadblock for United States biotechnology innovators to commercialization is proving that their products and processes can scale, thus showing investors a path to financial return; (2) the United States faces several main challenges to securing the broad range of infrastructure needed for the breadth of products that biotechnology can make, which are that— (A) the United States lacks sufficient biomanufacturing capacity, including because researchers are generating new products faster than manufacturing capacity is increasing and building new facilities is expensive and time-consuming; and (B) biomanufacturing technologies of the future have yet to mature into routine commercial applications, as current biomanufacturing facilities are generally optimized for 1 type of product and are usually not compatible with other products; and (3) to position the United States as a leader in bioindustrial innovation and enable participation in groundbreaking projects through state-of-the-art infrastructure, it is critical to establish technology maturation facilities to provide world-class capabilities.